Researchers from The University of Texas MD Anderson Cancer Center and Sarah Cannon Research Institute have used ripretinib and surgical removal of a tumour to successfully treat a patient with recurring gastrointestinal cancer, carrying a KIT exon 11 mutation. The patient received 43 months of treatment, longer than current ripretinib clinical trials, which are reported to have improved clinical outcomes.
Cyber expert speaks on Winston-Salem cyber incident – WFMYNews2.com
A cyber expert provided insight and analysis on a cyber incident in Winston-Salem in a report on WFMYNews2.com. The article likely discussed the details of
